NCT06854159View on ClinicalTrials.gov

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

February 1, 2029

Study Completion Date

April 30, 2029

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Receive CAR T-cell therapy

BIOLOGICAL

Odronextamab

Given IV

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Joseph Tuscano

OTHER

NCT06854159 - Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | Biotech Hunter | Biotech Hunter